வணிக வளர்ச்சி டெபிட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வணிக வளர்ச்சி டெபிட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வணிக வளர்ச்சி டெபிட் Today - Breaking & Trending Today

Meiji Seika Pharma Co., Ltd.: Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis

(1)
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, Meiji ) today announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of phase III multi-regional clinical trial in patients with plaque psoriasis. Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, Dong-A ).
DMB-3115 is a proposed biosimilar to ustekinumab, a recombinant monoclonal antibody for the treatment of patients with several inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn s disease and ulcerative colitis. Meiji and Dong-A are co-developing DMB-3115 under the strategic collaboration partnership agreement on biosimilars signed in September 2011. DMB-3115 i ....

Soult Ukpyolsi , South Korea , United States , Daikichiro Kobayashi , Kostenloser Wertpapierhandel , Jong Hyun Han , Business Development Dept , Donga Socio Holdings Headquarters , Meiji Seika Pharma Co Ltd , Representative Director , Donga Socio Holdings , Product Acquisition , Business Development , தெற்கு கொரியா , ஒன்றுபட்டது மாநிலங்களில் , வணிக வளர்ச்சி டெபிட் , பிரதிநிதி இயக்குனர் , டோங்கா சமூக ஹோல்டிங்ஸ் , ப்ராடக்ட் கையகப்படுத்தல் , வணிக வளர்ச்சி ,

Meiji Seika Pharma Co., Ltd.: CORRECTING and REPLACING Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis

(0)
First paragraph, third sentence of release dated May 20, 2021, should read: Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: JUNG Jae-Hun, Dong-A ). (instead of Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, Dong-A ).).
The updated release reads:
MEIJI SEIKA PHARMA:
PROMISING RESULTS OF PHASE I CLINICAL TRIAL OF DMB-3115, A PROPOSED USTEKINUMAB BIOSIMILAR, AND INITIATION OF PHASE III CLINICAL TRIAL IN PATIENTS WITH PLAQUE PSORIASIS
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, Meiji ) today announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of pha ....

Soult Ukpyolsi , South Korea , United States , Daikichiro Kobayashi , Kostenloser Wertpapierhandel , Jong Hyun Han , Business Development Dept , Donga Socio Holdings Headquarters , Meiji Seika Pharma Co Ltd , Donga Socio Holdings , Representative Director , Product Acquisition , Business Development , தெற்கு கொரியா , ஒன்றுபட்டது மாநிலங்களில் , வணிக வளர்ச்சி டெபிட் , டோங்கா சமூக ஹோல்டிங்ஸ் , பிரதிநிதி இயக்குனர் , ப்ராடக்ட் கையகப்படுத்தல் , வணிக வளர்ச்சி ,